Alfuzosin/voriconazole interaction

Alfuzosin/voriconazole interaction Reactions 1704, p23 - 2 Jun 2018 Blood pressure decreased: case report A 69-year-old man experienced a decrease in blood pressure following concurrent administration of alfuzosin and voriconazole [routes, dosages, duration of treatments to reaction onsets and outcome not stated]. The man had a medical history of acute myeloid leukaemia and urinary disorders. Due to invasive pulmonary aspergillosis he received treatment with voriconazole. He was also receiving treatment with alfuzosin for the urinary disorders for a year. When he visited the regular pharmacist, a drug interaction between alfuzosin and voriconazole was detected. The potent inhibitor of cytochrome (CYP) 3A4 (voriconazole) are contraindicated with the urologic alpha-blocker (alfuzosin). The treatment with voriconazole was initiated during the hospitalisation and a drop in blood pressure was noted. The pharmacist had a discussion with the haematologist, who had prescribed voriconazole to the patient and informed about the contraindication. The man’s treatment with alfuzosin was discontinued and he was treated with tamsulosin for the underlying urinary disorders. Author comment: At most, it is possible to suggest a decrease in the dosage of alpha-blocker when faced with a patient in whom side effects such as dizziness or orthostatic hypotension occur when a potent inhibitor is introduced. Voriconazole was started in hospital, the initial hospital treatment of the aspergillosis was able to detect a drop in blood pressure and educate the patient on the reasons for or against the interruption alfuzosin. Bensalah N, et al. How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4. [Review] [French]. Progres en Urologie 27: 275-282, No. 5, Apr 2017. Available from: URL: http://doi.org/10.1016/j.purol.2017.02.003 [French; summarised from a translation] - France 803324049 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Alfuzosin/voriconazole interaction

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/alfuzosin-voriconazole-interaction-3FZGUGt030
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46666-6
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p23 - 2 Jun 2018 Blood pressure decreased: case report A 69-year-old man experienced a decrease in blood pressure following concurrent administration of alfuzosin and voriconazole [routes, dosages, duration of treatments to reaction onsets and outcome not stated]. The man had a medical history of acute myeloid leukaemia and urinary disorders. Due to invasive pulmonary aspergillosis he received treatment with voriconazole. He was also receiving treatment with alfuzosin for the urinary disorders for a year. When he visited the regular pharmacist, a drug interaction between alfuzosin and voriconazole was detected. The potent inhibitor of cytochrome (CYP) 3A4 (voriconazole) are contraindicated with the urologic alpha-blocker (alfuzosin). The treatment with voriconazole was initiated during the hospitalisation and a drop in blood pressure was noted. The pharmacist had a discussion with the haematologist, who had prescribed voriconazole to the patient and informed about the contraindication. The man’s treatment with alfuzosin was discontinued and he was treated with tamsulosin for the underlying urinary disorders. Author comment: At most, it is possible to suggest a decrease in the dosage of alpha-blocker when faced with a patient in whom side effects such as dizziness or orthostatic hypotension occur when a potent inhibitor is introduced. Voriconazole was started in hospital, the initial hospital treatment of the aspergillosis was able to detect a drop in blood pressure and educate the patient on the reasons for or against the interruption alfuzosin. Bensalah N, et al. How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4. [Review] [French]. Progres en Urologie 27: 275-282, No. 5, Apr 2017. Available from: URL: http://doi.org/10.1016/j.purol.2017.02.003 [French; summarised from a translation] - France 803324049 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off